Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Market Movers Today: Dr Pepper Snapple Group Inc. (DPS), Immersion Corporation (IMMR), Aradigm Corporation (ARDM), and More

Dr Pepper Snapple Group Inc. (NYSE:DPS) (MarketWatch)
Dr Pepper Snapple Group Inc. DPS, +23.92% and Keurig Green Mountain announced plans Monday to merge, creating Keurig Dr Pepper. Dr Pepper Snapple shareholders will receive $103.75 per share as a special cash dividend and hold on to 13% of the newly merged company. Keurig shareholders will hold the other 87%. Dr Pepper Snapple shares shot up 39% in premarket trading after the announcement. The combined company would have pro forma revenue of about $11 billion.

Immersion Corporation (NASDAQ:IMMR) (The Motley Fool)
What happened: Shares of Immersion Corporation (NASDAQ:IMMR) have skyrocketed today, up by 50% as of 11:15 a.m. EST, after the company announced it had reached a settlement with Apple (NASDAQ:AAPL). As part of the settlement, Immersion also entered into a licensing agreement with the iPhone maker. So what: Immersion had first filed suit against Apple in February 2016, alleging patent infringement related to the use of haptic feedback in Apple products, while simultaneously lodging a formal complaint with the U.S. International Trade Commission.

Phongphan/Shutterstock.com

Phongphan/Shutterstock.com

Aradigm Corporation (NASDAQ:ARDM) (Benzinga)
Aradigm Corporation (NASDAQ:ARDM) shares dipped 20.5 percent to $1.78 after the pharmaceutical company that focuses on severe respiratory diseases announced a disappointing update. The company said the U.S. Food and Drug Administration won’t approve its Linhaliq NDA in its present form due to multiple areas of concerns, including clinical data, product quality, and human factors.

ABLYNX NV/ADR (NASDAQ:ABLX) (CNBC)
Ablynx – Ablynx agreed to be bought by French drugmaker Sanofi. Sanofi beat out Novo Nordisk in the bidding for the Belgian biotech company, agreeing to pay $4.8 billion. Ablynx had rejected a roughly $3.2 billion offer from Novo Nordisk.

Loading...